Thursday , October 28 2021

Researchers reach their goal of the 1st effective treatment against Ebola – Medgazette 24



[ad_1]

Researchers are a little closer to the possibility of repairing the dangerous hemorrhagic fever after two test medications have indicated survival steps of around 90% in clinical prognosis in the Congo.

Two research drugs – a Regeneron-created neutralizing drug called REGN-EB3 and a monoclonal immune response called mAb114 – will currently be offered to all patients infected with the virus in a blaze in the Democratic Republic of Congo (DRC). .

The drugs have shown "unbelievably better" results, according to the US National Institute of Allergy and Infectious Diseases (NIAID), in a preface to four possible medications led during the second-largest Ebola episode ever, currently entering its second year in DRC.

The drugs have improved survival rates of the disease more than two different drugs tested – ZMapp, made by Mapp Biopharmaceutical, and Remdesivir, developed by Gilead Sciences and those items are currently down, said Anthony Fauci, one of the co-traveling scientists. the prologue.

The office said that 49% of the patients on ZMapp and 53% of Remdesivir kicked the bucket in the investigation. On examination, 29% of the patients with REGN-EB3 and 34% of mAb114 passed.

Jean-Jacques Muyembe, Congo's chief of staff, Institut National de Recherche Biomédicale in DRC, who co-led the preface, said the results imply that "from now on and into the foreseeable future, we will never say that Ebola is hopeless . "

"These advances will help save a lot of life," he told columnists.

Anthony Fauci, chief of NIAID, further said the results are "very current news" for the fight against Ebola.

The office said that of the patients who were treated, they were treated with foci with low degrees of infection recognized in their blood, 94% who received REGN-EB3 and 89% who support mAb114.

In correlation, 66% of patients receiving Remdesivir and almost 75% of ZMapp support.

Ebola has been spreading in eastern Congo since August 2018 due to an episode that killed 1,800 individuals in each case. Efforts to control it were hampered by brutality from the state army and some neighborhood protections against foreign aid.

Ebola hemorrhagic fever, Institut National de Recherche Biomédicale, Jean-Jacques Muyembe, National Institute of Allergy and Infectious Diseases, Remdesivir, ZMapp

[ad_2]
Source link